<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725439</url>
  </required_header>
  <id_info>
    <org_study_id>BT0700BEL001</org_study_id>
    <nct_id>NCT00725439</nct_id>
  </id_info>
  <brief_title>An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne</brief_title>
  <official_title>An Open Label Pilot Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment of Moderate to Severe Facial Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is looking at a new oral drug to treat acne. All patients in the study will get
      active drug, there is no placebo arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Facial Lesion Count</measure>
    <time_frame>Post 12 weeks treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talarozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talarozole</intervention_name>
    <description>Oral Dose 1.0 mg once daily</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Rambazole</other_name>
    <other_name>R115866</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subject

          -  Presence of moderate to severe facial acne vulgaris: having a minimum of 15 papules
             and/or pustules and at least 2 nodulocystic lesions

          -  In good general health and free of any disease state or physical condition which, in
             the investigator's opinion, might have impaired evaluation of acne or exposed the
             subject to an unacceptable risk by trial participation

        Exclusion Criteria:

          -  Subjects with types of acne other than acne vulgaris

          -  Significant coexisting hepatic, renal, or bone marrow disease, hyperlipidemia, chronic
             pancreatitis, osteoporosis, or a history indicating adrenal cortex dysfunction or any
             other serious disease (including cancer and subjects known to be HIV positive)

          -  History of any malignancy in the past 5 years, except for adequately treated basal
             cell carcinoma of the skin

          -  History of heart failure, myocardial infarction within the past six months, cardiac
             arrhythmia, or under treatment for heart disorders

          -  Clinically significant abnormal ECG-intervals or morphology of the ECG; QT or QTc &gt;470
             ms in females or &gt;450 ms in males

          -  Use of vitamin A (&gt;1000 microgram/day), phenytoin, carbamazepine, warfarin,
             rifampicin, tetracyclines, ketoconazole, itraconazole, astemizole, terfenadine,
             cisapride, anti-psychotics, anti-depressants, lithium, antimalarials, alpha-blocking
             drugs, angiotensin-converting enzyme inhibitors, cyclosporin A, glucocorticosteroids
             and non-steroid anti-inflammatory drugs, non-potassium-sparing diuretics

          -  Use of oral retinoids 6 months prior to Visit 1

          -  Use of other oral/topical therapy for acne unless stopped at Visit 1

          -  Use of ultraviolet light (including artificial UVA and UVB as well as excessive
             natural sun exposure) unless stopped at Visit 1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. D. Roseeuw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Dermatology, University Hospital Brussel (UZ Brussel)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice in Dermatology</name>
      <address>
        <city>Vilvoorde</city>
        <zip>B-1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital, Dermatology</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>NL-3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <last_update_submitted>September 23, 2011</last_update_submitted>
  <last_update_submitted_qc>September 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>R 115866</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

